IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure
Attached as Exhibit 99.1 to this Item 7.01 is a presentation of
Eton Pharmaceuticals, Inc. (Eton), a subsidiary of Imprimis
Pharmaceuticals, Inc. (the Company), that is being used by the
management of the Company at investor conferences and at meetings
describing Eton and the Company.
The information contained in Item 7.01 of this report and in
Exhibit 99.1 shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 |
Eton Pharmaceuticals, Inc. presentation dated May 2017 |
About IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY)
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas. IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Recent Trading Information
IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) closed its last trading session down -0.08 at 3.53 with 180,509 shares trading hands.
